Business
Oncolytics Biotech(R) Appoints Experienced Financial and Strategic Leader Leonard Kruimer to Board of Directors
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 17, 2019 / Oncolytics Biotech ® ...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"Oncolytics Biotech(R) Appoints Experienced Financial and Strategic Leader Leonard Kruimer to Board of DirectorsSAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 17, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, is pleased to announce the appointment of Leonard Kruimer, MBA, CPA, to Oncolytics' Board of Directors.Mr. Kruimer has more than 30 years of experience in corporate finance, planning and strategy, including 20 years in senior management positions in private and publicly listed biotechnology and life science companies. Notably, Mr. Kruimer served as CFO and Executive Committee Member of the Netherlands-based vaccine company Crucell from 1998 through 2011, and an integral part of the corporate sale to Johnson & Johnson for US$2.3 billion. During his tenure, he led financing activities of the company, including its IPO on Nasdaq and Euronext in 2000 and subsequent listing on the Swiss Stock Exchange in 2006 and contributed to Crucell's strategic US$450 million acquisition and integration of Swiss-based Berna Biotech.\"We are excited and honored that Mr. Kruimer has chosen to join Oncolytics as a member of our Board of Directors. His capital markets, M&A, and financial expertise will be invaluable to Oncolytics as we advance pelareorep through multiple clinical studies in collaboration with leading pharma partners and academic institutions,\" said Mr. Wayne Pisano, Chairman of the Board of Oncolytics Biotech. \"We will glean tremendous benefit from his substantial strategic planning and leadership experience as a CFO and public company board member.\"\"I'm delighted to join Oncolytics at such a transformational time, as the company completes ongoing biomarker studies in order to prepare for a phase three registration study in metastatic breast cancer,\" said Mr. Kruimer. \"I look forward to working closely with the other members of the board and the management team, and to bring my financial and business development experience in the industry to bare on what will be an incredibly exciting time of clinical advancement and business growth for Oncolytics.\"Currently, Mr. Kruimer serves as an independent director and Chairman of the Audit Committee for Zealand Pharma (Nasdaq: ZEAL). He is Chairman of the Board of BioInve...